高碳酸血症与高碳酸性酸中毒对机械通气患者住院死亡率的影响
该多中心、两国回顾性研究分析了澳大利亚和新西兰171个ICU、14年间252,812例机械通气患者,按入ICU后24小时内pH与二氧化碳水平分为三组:正常碳酸血症伴正常pH(110,104例)、代偿性高碳酸血症(正常pH伴二氧化碳升高,20,463例)和高碳酸性酸中毒(122,245例)。高碳酸性酸中毒组病情更重(APACHE III评分68.6 vs 53.2 vs 49.2),住院死亡率最高,正常碳酸血症伴正常pH组最低。校正病情严重度后,高碳酸性酸中毒组住院死亡率的校正OR为1.74(95%CI 1.62-1.88),代偿性高碳酸血症组为1.18(95%CI 1.10-1.26),均高于正常碳酸血症伴正常pH组(P<0.001)。高碳酸性酸中毒患者中,死亡率随PCO2升高而增加,直至65 mm Hg后趋于平台。
要点
- 机械通气患者入ICU后24小时内出现高碳酸性酸中毒,校正病情严重度后住院死亡率升高(OR 1.74,95%CI 1.62-1.88)。
- 代偿性高碳酸血症(正常pH伴二氧化碳升高)亦与住院死亡率升高独立相关(OR 1.18,95%CI 1.10-1.26)。
- 高碳酸性酸中毒患者中,住院死亡率随PCO2升高而增加,直至65 mm Hg后趋于平台。
- 三组APACHE III评分分别为正常碳酸血症组49.2、代偿性高碳酸血症组53.2、高碳酸性酸中毒组68.6(P<0.01),高碳酸性酸中毒组病情最重。
- 研究为回顾性设计,仅显示相关性,不能推断高碳酸血症与死亡率的因果关系。
适用人群与场景
- 澳大利亚和新西兰171个ICU中接受有创机械通气的成人患者,数据来自澳大利亚和新西兰重症监护学会结局与资源评价中心成人患者数据库,覆盖14年期间。
- 按入ICU后24小时内pH与二氧化碳水平组合分为三组:正常碳酸血症伴正常pH、代偿性高碳酸血症(正常pH伴二氧化碳升高)、高碳酸性酸中毒。
诊断标准与关键阈值
- 分组依据为入ICU后24小时内pH与二氧化碳水平的组合:正常碳酸血症伴正常pH、代偿性高碳酸血症(正常pH伴二氧化碳升高)、高碳酸性酸中毒。
- 高碳酸性酸中毒患者中,住院死亡率随PCO2升高而增加,直至65 mm Hg后趋于平台。
研究设计与关键结果
- 研究类型为多中心、两国回顾性研究,纳入252,812例机械通气患者,来自171个ICU,数据覆盖14年。
- 三组例数:正常碳酸血症伴正常pH组110,104例,代偿性高碳酸血症组20,463例,高碳酸性酸中毒组122,245例。
- 三组APACHE III评分分别为49.2、53.2、68.6(P<0.01)。
- 住院死亡率在高碳酸性酸中毒组最高,正常碳酸血症伴正常pH组最低。
- 校正病情严重度后,高碳酸性酸中毒组住院死亡率OR为1.74(95%CI 1.62-1.88),代偿性高碳酸血症组OR为1.18(95%CI 1.10-1.26),均高于正常碳酸血症伴正常pH组(P<0.001)。
- 高碳酸性酸中毒患者中,住院死亡率随PCO2升高而增加,直至65 mm Hg后趋于平台。
证据类型、等级与局限
- 证据类型:多中心、两国回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该研究提示,机械通气患者入ICU后24小时内出现高碳酸性酸中毒与住院死亡率升高独立相关,代偿性高碳酸血症亦与死亡率升高相关,临床中对此类患者应关注其风险。
- 研究为回顾性设计,仅显示相关性,不能推断因果关系,作者未据此给出治疗推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Lung-protective ventilation is used to prevent further lung injury in patients on invasive mechanical ventilation. However, lung-protective ventilation can cause hypercapnia and hypercapnic acidosis. There are no large clinical studies evaluating the effects of hypercapnia and hypercapnic acidosis in patients requiring mechanical ventilation.
DESIGN: Multicenter, binational, retrospective study aimed to assess the impact of compensated hypercapnia and hypercapnic acidosis in patients receiving mechanical ventilation.
SETTINGS: Data were extracted from the Australian and New Zealand Intensive Care Society Centre for Outcome and Resource Evaluation Adult Patient Database over a 14-year period where 171 ICUs contributed deidentified data.
PATIENTS: Patients were classified into three groups based on a combination of pH and carbon dioxide levels (normocapnia and normal pH, compensated hypercapnia [normal pH with elevated carbon dioxide], and hypercapnic acidosis) during the first 24 hours of ICU stay. Logistic regression analysis was used to identify the independent association of hypercapnia and hypercapnic acidosis with hospital mortality.
MEASUREMENTS AND MAIN RESULTS: A total of 252,812 patients (normocapnia and normal pH, 110,104; compensated hypercapnia, 20,463; and hypercapnic acidosis, 122,245) were included in analysis. Patients with compensated hypercapnia and hypercapnic acidosis had higher Acute Physiology and Chronic Health Evaluation III scores (49.2 vs 53.2 vs 68.6; p < 0.01). The mortality was higher in hypercapnic acidosis patients when compared with other groups, with the lowest mortality in patients with normocapnia and normal pH. After adjusting for severity of illness, the adjusted odds ratio for hospital mortality was higher in hypercapnic acidosis patients (odds ratio, 1.74; 95% CI, 1.62-1.88) and compensated hypercapnia (odds ratio, 1.18; 95% CI, 1.10-1.26) when compared with patients with normocapnia and normal pH (p < 0.001). In patients with hypercapnic acidosis, the mortality increased with increasing PCO2 until 65 mm Hg after which the mortality plateaued.
CONCLUSIONS: Hypercapnic acidosis during the first 24 hours of intensive care admission is more strongly associated with increased hospital mortality than compensated hypercapnia or normocapnia.
参考来源
- Tiruvoipati R, Pilcher D, Buscher H, et al. Effects of Hypercapnia and Hypercapnic Acidosis on Hospital Mortality in Mechanically Ventilated Patients. Crit Care Med. 2017. PMID: 28406813. doi:10.1097/CCM.0000000000002332
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。